Angela Elhebieshy

The development of tumor targeting antibodies has been prominently on the rise in the recent years. The design of such antibodies varies from recombinant antibodies to antibody-drug conjugates or bi-specific antibodies. The potential for further growth of therapeutic antibodies is enormous, however, it is challenged by the limited number of tumor specific proteins that can be safely targeted. To tackle the lack of specificity of tumor antibody therapy, we are developing a novel targeting method.